You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞士諾華藥廠同意羅氏藥廠購回所持股份 套現207億美元
阿思達克 11-04 17:05
瑞士諾華藥廠(Novartis)(NVS.US)同意讓同業羅氏藥廠(Roche)(RHHBY.US)購回前者所持股份,涉及5,330萬股,每股作價356.93瑞士法郎(388.99美元),即羅氏藥廠非投票權股票截至11月2日止20個交易日的平均價格,總計涉及資金207億美元。 諾華藥廠行政總裁Vas Narasimhan表示,公司作爲羅氏藥廠股東20年後,認爲目前是把投資折現的時機,有關決定符合公司策略目標,並擬把售股所得用作投資,以最大化股東價值及繼續研發藥物。諾華藥廠料是次出售將獲得溢利140億美元。 羅氏藥廠表示,是次透過債務融資的購回股份行動有附帶達成條件,包括有關股份回購後被註銷時,資本總額可獲減少,以及用作交易的中期業績報告獲得通過。羅氏藥廠又指,與諾華藥廠脫離關係後,將給予公司全面策略彈性。公司同時確認今年業務展望及希望今年增加派息。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account